Sanofi’s blockbuster skin and asthma drug Dupixent significantly reduced itching in patients with chronic hives, paving the way for the resubmission of the drug for this condition.
Related by source
-
New Zealand Moves to Change Law After Uber Loses Contractor Case
-
Thai State Fund Seeks $4.5 Billion to Help Boost Stock Market
-
FBI Says Trump Was Subject of Apparent Assassination Attempt: AP
-
Trump Is Safe After Apparent Assassination Attempt in Florida
-
Extraprofitti, La Russa risponde a Tajani: “Non serve inalberarsi”
-
What Fed Rate Cuts Mean to Finance Chiefs
-
SMCI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Super Micro Computer, Inc....
-
OFIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Orthofix Medical Inc. Inve...
-
Politan Comments on Masimo’s Latest Attempt to Block a Fair Shareholder Vote
-
Gunshots Heard Near Trump’s Golf Course, No Injuries Reported
-
Fed Ready to Unshackle US Economy With Soft Landing at Stake
-
Mathias Döpfner, KKR Said to Near Deal on Axel Springer Split
